<DOC>
	<DOCNO>NCT01414855</DOCNO>
	<brief_summary>This open-label , multicenter study evaluate efficacy safety obinutuzumab [ RO5072759 ( GA101 ) ] combination CHOP ( Cyclophosphamide , Doxorubicin , Vincristine , Prednisone ) chemotherapy patient advance diffuse large B-cell lymphoma . Patients receive 8 cycle obinutuzumab ( 1000 mg intravenously Day 1 21-day cycle , Cycle 1 obinutuzumab also infuse Days 8 15 ) combination CHOP chemotherapy Day 1 cycle 1 6 . A substudy investigate drug-drug interaction obinutuzumab CHOP chemotherapy agent . For substudy , additional cohort approximately 15 patient plan enrolled subset investigational site .</brief_summary>
	<brief_title>A Study Obinutuzumab RO5072759 ( GA101 ) Combination With CHOP Chemotherapy Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma ( GATHER )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Adult patient , ≥18 year age Previously untreated cluster differentiation antigen 20 ( CD20 ) positive diffuse large Bcell lymphoma Ann Arbour Stage III/IV bulky II ( mass &gt; 10 cm ) At least one bidimensionally measurable lesion define &gt; 1.5 cm large dimension CT scan Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 Left ventricular ejection fraction ≥50 % Adequate hematologic function Transformed lymphoma ( follicular IIIB ) previously treat chemotherapy immunotherapy Prior therapy diffuse large Bcell lymphoma except nodal biopsy local irradiation Central nervous system ( CNS ) lymphoma , primary mediastinal large cell lymphoma , primary cutaneous lymphoma , primary effusion lymphoma Patients receive cytotoxic drug rituximab part treatment another condition ( e.g . rheumatoid arthritis ) prior use antiCD20 antibody Chemotherapy investigational therapy within 28 day prior start Cycle 1 Contraindication individual component CHOP , include prior receipt anthracyclines History severe allergic anaphylactic reaction monoclonal antibody therapy History malignancy , except curatively treat basal squamous cell carcinoma melanoma skin situ carcinoma cervix , malignancy treat without curative intent remission without treatment ≥2 year prior enrolment Positive hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) human Tcell leukemia virus ( HTLV1 ) infection Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>